# Vaccine and Treatment Evaluation Unit:Phase II Pertussis Vaccine Trial

> **NIH NIH N01** · UNIVERSITY OF MARYLAND BALTIMORE · 2022 · $537,930

## Abstract

This program is comprised of a consortium of individual contracts within academic centers and organizations that provide a ready resource for the design and conduct of clinical trials to evaluate promising products to combat infectious diseases. In general, products will be evaluated in normal healthy populations; however, access to special populations is also available.

## Key facts

- **NIH application ID:** 10670674
- **Project number:** 272201300022I-P00005-27200022-1
- **Recipient organization:** UNIVERSITY OF MARYLAND BALTIMORE
- **Principal Investigator:** MICHELLE MEDEIROS
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $537,930
- **Award type:** —
- **Project period:** 2017-09-11 → 2022-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10670674

## Citation

> US National Institutes of Health, RePORTER application 10670674, Vaccine and Treatment Evaluation Unit:Phase II Pertussis Vaccine Trial (272201300022I-P00005-27200022-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10670674. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*